{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T03:54:14Z","timestamp":1789530854839,"version":"build-2803163510"},"reference-count":210,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,6,19]],"date-time":"2022-06-19T00:00:00Z","timestamp":1655596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Malaya Faculty of Medicine Research","award":["GPF003C-2019"],"award-info":[{"award-number":["GPF003C-2019"]}]},{"name":"University of Malaya Faculty of Medicine Research","award":["UM.0000092\/KWD.BH"],"award-info":[{"award-number":["UM.0000092\/KWD.BH"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Autosomal recessive cerebellar ataxias (ARCAs) are a heterogeneous group of rare neurodegenerative inherited disorders. The resulting motor incoordination and progressive functional disabilities lead to reduced lifespan. There is currently no cure for ARCAs, likely attributed to the lack of understanding of the multifaceted roles of antioxidant defense and the underlying mechanisms. This systematic review aims to evaluate the extant literature on the current developments of therapeutic strategies that target oxidative stress for the management of ARCAs. We searched PubMed, Web of Science, and Science Direct Scopus for relevant peer-reviewed articles published from 1 January 2016 onwards. A total of 28 preclinical studies fulfilled the eligibility criteria for inclusion in this systematic review. We first evaluated the altered cellular processes, abnormal signaling cascades, and disrupted protein quality control underlying the pathogenesis of ARCA. We then examined the current potential therapeutic strategies for ARCAs, including aromatic, organic and pharmacological compounds, gene therapy, natural products, and nanotechnology, as well as their associated antioxidant pathways and modes of action. We then discussed their potential as antioxidant therapeutics for ARCAs, with the long-term view toward their possible translation to clinical practice. In conclusion, our current understanding is that these antioxidant therapies show promise in improving or halting the progression of ARCAs. Tailoring the therapies to specific disease stages could greatly facilitate the management of ARCAs.<\/jats:p>","DOI":"10.3390\/ph15060764","type":"journal-article","created":{"date-parts":[[2022,6,19]],"date-time":"2022-06-19T21:19:26Z","timestamp":1655673566000},"page":"764","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Discovery of Therapeutics Targeting Oxidative Stress in Autosomal Recessive Cerebellar Ataxia: A Systematic Review"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5402-6869","authenticated-orcid":false,"given":"Sze Yuen","family":"Lew","sequence":"first","affiliation":[{"name":"Department of Anatomy, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 50603, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Weng Lok","family":"Phang","sequence":"additional","affiliation":[{"name":"Department of Anatomy, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 50603, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pit Shan","family":"Chong","sequence":"additional","affiliation":[{"name":"Neuromodulation Laboratory, School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8934-738X","authenticated-orcid":false,"given":"Jaydeep","family":"Roy","sequence":"additional","affiliation":[{"name":"Neuromodulation Laboratory, School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7275-0351","authenticated-orcid":false,"given":"Chi Him","family":"Poon","sequence":"additional","affiliation":[{"name":"Neuromodulation Laboratory, School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing Shan","family":"Yu","sequence":"additional","affiliation":[{"name":"Neuromodulation Laboratory, School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6692-6285","authenticated-orcid":false,"given":"Lee Wei","family":"Lim","sequence":"additional","affiliation":[{"name":"Neuromodulation Laboratory, School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5669-8987","authenticated-orcid":false,"given":"Kah Hui","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Anatomy, Faculty of Medicine, Universiti Malaya, Kuala Lumpur 50603, Malaysia"},{"name":"Neuromodulation Laboratory, School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1750-1172-1-47","article-title":"Autosomal recessive cerebellar ataxias","volume":"1","author":"Palau","year":"2006","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1590\/S0004-282X2009000600036","article-title":"Autosomal recessive ataxias: 20 types, and counting","volume":"67","author":"Martyn","year":"2009","journal-title":"Arq. Neuropsiquiatr."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000358801","article-title":"The global epidemiology of hereditary ataxia and spastic paraplegia: A systematic review of prevalence studies","volume":"42","author":"Ruano","year":"2014","journal-title":"Neuroepidemiology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/WCO.0000000000000774","article-title":"Cerebellar ataxias: An update","volume":"33","author":"Manto","year":"2020","journal-title":"Curr. Opin. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Manto, M.U. (2010). Autosomal recessive cerebellar ataxias. Cerebellar Disorders: A Practical Approach to Diagnosis and Management, Cambridge University Press.","DOI":"10.1017\/CBO9780511750557"},{"key":"ref_6","unstructured":"Daroff, R., Jankovic, J., Mazziotta, J., and Pomeroy, S. (2015). Clinical neurogenetics. Bradley\u2019s Neurology in Clinical Practice, Elsevier. [7th ed.]."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1056\/NEJMra1006610","article-title":"The autosomal recessive cerebellar ataxias","volume":"366","author":"Anheim","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/B978-0-444-63233-3.00013-0","article-title":"Autosomal-recessive cerebellar ataxias","volume":"147","author":"Fogel","year":"2018","journal-title":"Handb. Clin. Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/mds.27415","article-title":"The genetic nomenclature of recessive cerebellar ataxias","volume":"33","author":"Rossi","year":"2018","journal-title":"Mov. Disord."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1007\/s12311-019-01052-2","article-title":"The classification of autosomal recessive cerebellar ataxias: A consensus statement from the society for research on the cerebellum and ataxias task force","volume":"18","author":"Beaudin","year":"2019","journal-title":"Cerebellum"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13020-020-00414-x","article-title":"Therapeutic roles of natural remedies in combating hereditary ataxia: A systematic review","volume":"16","author":"Phang","year":"2021","journal-title":"Chin. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1179\/1351000212Y.0000000005","article-title":"Oxidative stress as a cofactor in spinocerebellar ataxia type 2","volume":"17","year":"2012","journal-title":"Redox Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/mdc3.12057","article-title":"Treatment options in degenerative cerebellar ataxia: A systematic review","volume":"1","author":"Sarva","year":"2014","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1590\/0004-282X20160038","article-title":"Current concepts in the treatment of hereditary ataxias","volume":"74","author":"Pedroso","year":"2016","journal-title":"Arq. Neuropsiquiatr."},{"key":"ref_15","first-page":"CD007791","article-title":"Pharmacological treatments for Friedreich ataxia","volume":"8","author":"Kearney","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2174\/1871527317666180419115029","article-title":"Current and promising therapies in autosomal recessive ataxias","volume":"17","year":"2018","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1080\/14737175.2020.1821654","article-title":"Emerging therapies in Friedreich\u2019s ataxia","volume":"20","author":"Zesiewicz","year":"2020","journal-title":"Expert Rev. Neurother."},{"key":"ref_18","unstructured":"LeDoux, M. (2015). Genetics and clinical features of inherited ataxias. Movement Disorders: Genetics and Models, Academic Press. [2nd ed.]."},{"key":"ref_19","unstructured":"Adam, M.P., Ardinger, H.H., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Mirzaa, G., and Amemiya, A. (2016, October 27). Ataxia-Telangiectasia, GeneReviews\u00ae [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK26468\/."},{"key":"ref_20","unstructured":"Riboldi, G.M., Samanta, D., and Frucht, S. (2022, May 09). Ataxia Telangiectasia, StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK519542\/."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1080\/1744666X.2020.1810570","article-title":"Ataxia-telangiectasia: Epidemiology, pathogenesis, clinical phenotype, diagnosis, prognosis and management","volume":"16","author":"Amirifar","year":"2020","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Biagiotti, S., Bianchi, M., Rossi, L., Chessa, L., and Magnani, M. (2019). Activation of NRF2 by dexamethasone in ataxia telangiectasia cells involves KEAP1 inhibition but not the inhibition of p38. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0216668"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"8850708","DOI":"10.1155\/2021\/8850708","article-title":"Ataxia telangiectasia mutated protein kinase: A potential master puppeteer of oxidative stress-induced metabolic recycling","volume":"2021","author":"Blignaut","year":"2021","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.dnarep.2011.05.004","article-title":"ATM protects against oxidative stress induced by oxidized low-density lipoprotein","volume":"10","author":"Semlitsch","year":"2011","journal-title":"DNA Repair"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1182\/blood-2012-09-456897","article-title":"Pathogenesis of ataxia-telangiectasia: The next generation of ATM functions","volume":"121","author":"Ambrose","year":"2013","journal-title":"Blood"},{"key":"ref_26","first-page":"155","article-title":"Inhibitory effect of alpha-lipoic acid on mitochondrial dysfunction and interleukin-8 expression in interleukin-1beta-stimulated ataxia telangiectasia fibroblasts","volume":"71","author":"Yoon","year":"2020","journal-title":"J. Physiol. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1093\/hmg\/ddm166","article-title":"Intrinsic mitochondrial dysfunction in ATM-deficient lymphoblastoid cells","volume":"16","author":"Ambrose","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1093\/brain\/awg283","article-title":"Cerebellar ataxia with oculomotor apraxia type 1: Clinical and genetic studies","volume":"126","author":"Moreira","year":"2003","journal-title":"Brain"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1212\/01.WNL.0000137044.06573.46","article-title":"Aprataxin gene mutations in Tunisian families","volume":"63","author":"Amouri","year":"2004","journal-title":"Neurology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00415-004-0374-7","article-title":"Aprataxin mutations are a rare cause of early onset ataxia in Germany","volume":"251","author":"Habeck","year":"2004","journal-title":"J. Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10048-011-0281-x","article-title":"Ataxia with oculomotor apraxia type1 (AOA1): Novel and recurrent aprataxin mutations, coenzyme Q10 analyses, and clinical findings in Italian patients","volume":"12","author":"Castellotti","year":"2011","journal-title":"Neurogenetics"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1177\/08830738050200071701","article-title":"Type 1 ataxia with oculomotor apraxia with aprataxin gene mutations in two American children","volume":"20","author":"Tsao","year":"2005","journal-title":"J. Child Neurol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1212\/01.WNL.0000150588.75281.58","article-title":"Coenzyme Q deficiency and cerebellar ataxia associated with an aprataxin mutation","volume":"64","author":"Quinzii","year":"2005","journal-title":"Neurology"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Manto, M., Gruol, D., Schmahmann, J., Koibuchi, N., and Sillitoe, R. (2020). Autosomal recessive cerebellar ataxias. Handbook of the Cerebellum and Cerebellar Disorders, Springer.","DOI":"10.1007\/978-3-319-97911-3"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10048-009-0196-y","article-title":"Epidemiological, clinical, paraclinical and molecular study of a cohort of 102 patients affected with autosomal recessive progressive cerebellar ataxia from Alsace, Eastern France: Implications for clinical management","volume":"11","author":"Anheim","year":"2010","journal-title":"Neurogenetics"},{"key":"ref_36","unstructured":"Adam, M.P., Ardinger, H.H., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Mirzaa, G., and Amemiya, A. (2015, March 19). Ataxia with oculomotor apraxia type 1, GeneReviews\u00ae [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1456\/."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nature05164","article-title":"The neurodegenerative disease protein aprataxin resolves abortive DNA ligation intermediates","volume":"443","author":"Ahel","year":"2006","journal-title":"Nature"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1093\/nar\/gkz083","article-title":"Diminished OPA1 expression and impaired mitochondrial morphology and homeostasis in aprataxin-deficient cells","volume":"47","author":"Zheng","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e25230","DOI":"10.4161\/rdis.25230","article-title":"Senataxin protects the genome: Implications for neurodegeneration and other abnormalities","volume":"1","author":"Lavin","year":"2013","journal-title":"Rare Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/brain\/awh080","article-title":"Frequency and phenotypic spectrum of ataxia with oculomotor apraxia 2: A clinical and genetic study in 18 patients","volume":"127","author":"Bouslam","year":"2004","journal-title":"Brain"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jns.2008.12.004","article-title":"Ataxia with oculomotor apraxia type 2: A clinical and genetic study of 19 patients","volume":"278","author":"Tazir","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/PDM.0b013e318257ad9a","article-title":"Clinical and molecular findings of ataxia with oculomotor apraxia type 2 (AOA2) in 5 Tunisian families","volume":"21","author":"Hammer","year":"2012","journal-title":"Diagn. Mol. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/jhg.2009.104","article-title":"A novel nonsense mutation in a Japanese family with ataxia with oculomotor apraxia type 2 (AOA2)","volume":"54","author":"Nakamura","year":"2009","journal-title":"J. Hum. Genet."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Bohlega, S.A., Shinwari, J.M., Al Sharif, L.J., Khalil, D.S., Alkhairallah, T.S., and Al Tassan, N.A. (2011). Clinical and molecular characterization of ataxia with oculomotor apraxia patients in Saudi Arabia. BMC Med. Genet., 12.","DOI":"10.1186\/1471-2350-12-27"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Bernard, V., Minnerop, M., B\u00fcrk, K., Kreuz, F., Gillessen-Kaesbach, G., and Z\u00fchlke, C. (2009). Exon deletions and intragenic insertions are not rare in ataxia with oculomotor apraxia 2. BMC Med. Genet., 10.","DOI":"10.1186\/1471-2350-10-87"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3109\/00207454.2013.787616","article-title":"A new SETX mutation producing AOA2 in two siblings","volume":"123","author":"Datta","year":"2013","journal-title":"Int. J. Neurosci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1083\/jcb.200701042","article-title":"Senataxin, defective in ataxia oculomotor apraxia type 2, is involved in the defense against oxidative DNA damage","volume":"177","author":"Suraweera","year":"2007","journal-title":"J. Cell Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/sj.cdd.4402116","article-title":"A novel form of ataxia oculomotor apraxia characterized by oxidative stress and apoptosis resistance","volume":"14","author":"Gueven","year":"2007","journal-title":"Cell Death Differ."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJM199511163332003","article-title":"Adult-onset spinocerebellar dysfunction caused by a mutation in the gene for the alpha-tocopherol-transfer protein","volume":"333","author":"Gotoda","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000080092","article-title":"Prevalence of inherited ataxias in the province of Padua, Italy","volume":"23","author":"Zortea","year":"2004","journal-title":"Neuroepidemiology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/brain\/awt339","article-title":"Molecular, clinical and peripheral neuropathy study of Tunisian patients with ataxia with vitamin E deficiency","volume":"137","author":"Bouhlal","year":"2014","journal-title":"Brain"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"33","DOI":"10.14802\/jmd.14030","article-title":"Ataxia with vitamin E deficiency in Norway","volume":"8","author":"Elkamil","year":"2015","journal-title":"J. Mov. Disord."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1042\/bj3060437","article-title":"Human \u03b1-tocopherol transfer protein: cDNA cloning, expression and chromosomal localization","volume":"306","author":"Arita","year":"1995","journal-title":"Biochem. J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0006-8993(99)01090-2","article-title":"Localization of \u03b1-tocopherol transfer protein in the brains of patients with ataxia with vitamin E deficiency and other oxidative stress related neurodegenerative disorders","volume":"822","author":"Copp","year":"1999","journal-title":"Brain Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"17705","DOI":"10.1016\/S0021-9258(17)46761-5","article-title":"Primary structure of alpha-tocopherol transfer protein from rat liver. Homology with cellular retinaldehyde-binding protein","volume":"268","author":"Sato","year":"1993","journal-title":"J. Biol. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/10715760310001659611","article-title":"Localization of \u03b1-tocopherol transfer protein in trophoblast, fetal capillaries\u2019 endothelium and amnion epithelium of human term placenta","volume":"38","author":"Beninde","year":"2004","journal-title":"Free Radic. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0960-8966(98)00055-8","article-title":"Autosomal recessive spastic ataxia of Charlevoix\u2013Saguenay","volume":"8","author":"Bouchard","year":"1998","journal-title":"Neuromuscul. Disord."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/archneur.60.7.982","article-title":"Phenotypic features and genetic findings in sacsin-related autosomal recessive ataxia in Tunisia","volume":"60","author":"Lalani","year":"2003","journal-title":"Arch. Neurol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12031-009-9212-9","article-title":"A novel SACS gene mutation in a Tunisian family","volume":"39","author":"Bouhlal","year":"2009","journal-title":"J. Mol. Neurosci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10048-004-0179-y","article-title":"Private SACS mutations in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) families from Turkey","volume":"5","author":"Richter","year":"2004","journal-title":"Neurogenetics"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1212\/01.WNL.0000099371.14478.73","article-title":"Identification of a SACS gene missense mutation in ARSACS","volume":"62","author":"Ogawa","year":"2004","journal-title":"Neurology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1212\/01.WNL.0000104491.66816.77","article-title":"Novel SACS mutations in autosomal recessive spastic ataxia of Charlevoix-Saguenay type","volume":"62","author":"Grieco","year":"2004","journal-title":"Neurology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/mds.20579","article-title":"Novel mutation of SACS gene in a Spanish family with autosomal recessive spastic ataxia","volume":"20","author":"Criscuolo","year":"2005","journal-title":"Mov. Disord."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10048-008-0131-7","article-title":"ARSACS in the Dutch population: A frequent cause of early-onset cerebellar ataxia","volume":"9","author":"Vermeer","year":"2008","journal-title":"Neurogenetics"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/ejhg.2008.58","article-title":"A novel genomic disorder: A deletion of the SACS gene leading to spastic ataxia of Charlevoix-Saguenay","volume":"16","author":"Breckpot","year":"2008","journal-title":"Eur. J. Human. Genet."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jns.2007.07.022","article-title":"Novel SACS mutation in a Belgian family with sacsin-related ataxia","volume":"264","author":"Ouyang","year":"2008","journal-title":"J. Neurol. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1212\/WNL.0b013e3181f4d86c","article-title":"Mutations in SACS cause atypical and late-onset forms of ARSACS","volume":"75","author":"Baets","year":"2010","journal-title":"Neurology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s12311-019-01028-2","article-title":"ARSACS as a worldwide disease: Novel SACS mutations identified in a consanguineous family from the remote tribal Jammu and Kashmir Region in India","volume":"18","author":"Kuchay","year":"2019","journal-title":"Cerebellum"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1007\/s00415-018-8950-4","article-title":"Coordination and timing deficits in speech and swallowing in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS)","volume":"265","author":"Vogel","year":"2018","journal-title":"J. Neurol."},{"key":"ref_70","unstructured":"Adam, M.P., Ardinger, H.H., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Mirzaa, G., and Amemiya, A. (2020, January 02). ARSACS, GeneReviews\u00ae [Internet], Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/20301432\/."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1093\/hmg\/ddp067","article-title":"The ataxia protein sacsin is a functional co-chaperone that protects against polyglutamine-expanded ataxin-1","volume":"18","author":"Parfitt","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1073\/pnas.1113166109","article-title":"Mitochondrial dysfunction and Purkinje cell loss in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS)","volume":"109","author":"Girard","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_73","first-page":"3130","article-title":"Altered organization of the intermediate filament cytoskeleton and relocalization of proteostasis modulators in cells lacking the ataxia protein sacsin","volume":"26","author":"Duncan","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1007\/s00415-015-7911-4","article-title":"Powerhouse failure and oxidative damage in autosomal recessive spastic ataxia of Charlevoix-Saguenay","volume":"262","author":"Criscuolo","year":"2015","journal-title":"J. Neurol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nrneurol.2009.26","article-title":"Diagnosis and treatment of Friedreich ataxia: A European perspective","volume":"5","author":"Schulz","year":"2009","journal-title":"Nat. Rev. Neurol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/jnc.12215","article-title":"Prevalence gradients of Friedreich\u2019s ataxia and R1b haplotype in Europe co-localize, suggesting a common palaeolithic origin in the Franco-Cantabrian ice age refuge","volume":"126","author":"Vankan","year":"2013","journal-title":"J. Neurochem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.271.5254.1423","article-title":"Friedreich\u2019s ataxia: Autosomal recessive disease caused by an intronic GAA triplet repeat expansion","volume":"271","author":"Campuzano","year":"1996","journal-title":"Science"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00702-010-0503-7","article-title":"Iron-dependent functions of mitochondria--relation to neurodegeneration","volume":"118","author":"Gille","year":"2011","journal-title":"J. Neural Transm. (Vienna)"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.redox.2013.06.004","article-title":"Insights into the role of oxidative stress in the pathology of Friedreich ataxia using peroxidation resistant polyunsaturated fatty acids","volume":"1","author":"Cotticelli","year":"2013","journal-title":"Redox Biol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Richardson, T.E., Yu, A.E., Wen, Y., Yang, S.H., and Simpkins, J.W. (2012). Estrogen prevents oxidative damage to the mitochondria in Friedreich\u2019s ataxia skin fibroblasts. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0034600"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/1535370219890873","article-title":"Effects of tocotrienol supplementation in Friedreich\u2019s ataxia: A model of oxidative stress pathology","volume":"245","author":"Bolotta","year":"2020","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1212\/WNL.55.11.1752","article-title":"Increased levels of plasma malondialdehyde in Friedreich ataxia","volume":"55","author":"Emond","year":"2000","journal-title":"Neurology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1212\/WNL.55.11.1719","article-title":"Oxidative stress in patients with Friedreich ataxia","volume":"55","author":"Schulz","year":"2000","journal-title":"Neurology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1046\/j.1365-2362.2001.00922.x","article-title":"Glutathione in blood of patients with Friedreich\u2019s ataxia","volume":"31","author":"Piemonte","year":"2001","journal-title":"Eur. J. Clin. Invest."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/1873-3468.12928","article-title":"The role of oxidative stress in Friedreich\u2019s ataxia","volume":"592","author":"Lupoli","year":"2018","journal-title":"FEBS Lett."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/ene.12341","article-title":"EFNS\/ENS Consensus on the diagnosis and management of chronic ataxias in adulthood","volume":"21","author":"Boesch","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1038\/ncpneuro0833","article-title":"Reply to drug insight: Antioxidant therapy in inherited ataxias","volume":"4","author":"Gohil","year":"2008","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1590\/S0004-282X2011000300004","article-title":"Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS): Typical clinical and neuroimaging features in a Brazilian family","volume":"69","author":"Pedroso","year":"2011","journal-title":"Arq. Neuropsiquiatr."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/bmb\/ldm012","article-title":"Current and potential therapeutic strategies for the treatment of ataxia-telangiectasia","volume":"81","author":"Lavin","year":"2007","journal-title":"Br. Med. Bull."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"21295","DOI":"10.1074\/jbc.M501527200","article-title":"Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species. Implications for the use of exogenous ubiquinones as therapies and experimental tools","volume":"280","author":"James","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"112143","DOI":"10.1016\/j.biopha.2021.112143","article-title":"Plasma idebenone monitoring in Friedreich\u2019s ataxia patients during a long-term follow-up","volume":"143","author":"Cesar","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/archneurol.2010.168","article-title":"A phase 3, double-blind, placebo-controlled trial of idebenone in Friedreich ataxia","volume":"67","author":"Lynch","year":"2010","journal-title":"Arch. Neurol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ahj.2010.10.038","article-title":"Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA)","volume":"161","author":"Lagedrost","year":"2011","journal-title":"Am. Heart. J."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s00415-011-6174-y","article-title":"Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich\u2019s ataxia: Data from a 6-month controlled study followed by a 12-month open-label extension study","volume":"259","author":"Meier","year":"2012","journal-title":"J. Neurol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/ars.2007.1957","article-title":"Redox regulation of cell survival","volume":"10","author":"Trachootham","year":"2008","journal-title":"Antioxid. Redox Signal."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.biopha.2015.07.025","article-title":"Oxidative stress, mitochondrial dysfunction and neurodegenerative diseases; a mechanistic insight","volume":"74","author":"Bhat","year":"2015","journal-title":"Biomed. Pharmacother."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0028-3908(01)00019-3","article-title":"Oxidative stress induced-neurodegenerative diseases: The need for antioxidants that penetrate the blood brain barrier","volume":"40","author":"Melamed","year":"2001","journal-title":"Neuropharmacology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/ncpneuro0704","article-title":"Drug insight: Antioxidant therapy in inherited ataxias","volume":"4","author":"Pandolfo","year":"2008","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"ref_99","first-page":"431","article-title":"Experimental antioxidant therapy in ataxia telangiectasia","volume":"2","author":"Reliene","year":"2008","journal-title":"Clin. Med. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.3389\/fimmu.2018.01896","article-title":"The Nrf2-antioxidant response element signaling pathway controls fibrosis and autoimmunity in scleroderma","volume":"9","author":"Kavian","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1089\/ars.2017.7342","article-title":"Transcriptional regulation by Nrf2","volume":"29","author":"Tonelli","year":"2018","journal-title":"Antioxid. Redox Signal"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.redox.2015.12.005","article-title":"The novel triterpenoid RTA 408 protects human retinal pigment epithelial cells against H2O2-induced cell injury via NF-E2-related factor 2 (Nrf2) activation","volume":"8","author":"Liu","year":"2016","journal-title":"Redox Biol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/hmg\/ddaa023","article-title":"Correction of ATM mutations in iPS cells from two ataxia-telangiectasia patients restores DNA damage and oxidative stress responses","volume":"29","author":"Ovchinnikov","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1111\/febs.13901","article-title":"Dexamethasone improves redox state in ataxia telangiectasia cells by promoting an NRF2-mediated antioxidant response","volume":"283","author":"Biagiotti","year":"2016","journal-title":"FEBS J."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/s41418-018-0272-7","article-title":"GSE4 peptide suppresses oxidative and telomere deficiencies in ataxia telangiectasia patient cells","volume":"26","author":"Iarriccio","year":"2019","journal-title":"Cell Death Differ."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Inman, D.M., Lambert, W.S., Calkins, D.J., and Horner, P.J. (2013). \u03b1-lipoic acid antioxidant treatment limits glaucoma-related retinal ganglion cell death and dysfunction. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0065389"},{"key":"ref_107","unstructured":"Rakel, D. (2018). Alzheimer disease. Integrative Medicine, Elsevier. [4th ed.]."},{"key":"ref_108","unstructured":"Rakel, D. (2018). Insulin resistance and the metabolic syndrome. Integrative Medicine, Elsevier. [4th ed.]."},{"key":"ref_109","first-page":"3276958","article-title":"The effect of 600 mg alpha-lipoic acid supplementation on oxidative stress, inflammation, and RAGE in older adults with type 2 diabetes mellitus","volume":"2019","year":"2019","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_110","first-page":"1559","article-title":"Genome editing: A perspective on the application of CRISPR\/Cas9 to study human diseases","volume":"43","year":"2019","journal-title":"Int. J. Mol. Med."},{"key":"ref_111","unstructured":"Hemmings, H.C., and Egan, T.D. (2019). Pharmacology of postoperative nausea and vomiting. Pharmacology and Physiology for Anesthesia, Elsevier. [2nd ed.]."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1212\/NXI.0000000000000098","article-title":"Positive effect of erythrocyte-delivered dexamethasone in ataxia-telangiectasia","volume":"2","author":"Leuzzi","year":"2015","journal-title":"Neurol. Neuroimmunol. NeuroInflamm."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1182\/blood-2007-04-083261","article-title":"A dyskerin motif reactivates telomerase activity in X-linked dyskeratosis congenita and in telomerase-deficient human cells","volume":"111","author":"Sastre","year":"2008","journal-title":"Blood"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Iarriccio, L., Mangu\u00e1n-Garc\u00eda, C., Pintado-Berninches, L., Manche\u00f1o, J.M., Molina, A., Perona, R., and Sastre, L. (2015). GSE4, a small dyskerin-and GSE24.2-related peptide, induces telomerase activity, cell proliferation and reduces DNA damage, oxidative stress and cell senescence in dyskerin mutant cells. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0142980"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/sj.onc.1205060","article-title":"ATM function and telomere stability","volume":"21","author":"Pandita","year":"2002","journal-title":"Oncogene"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.arr.2016.05.009","article-title":"Telomere-associated aging disorders","volume":"33","author":"Opresko","year":"2017","journal-title":"Ageing Res. Rev."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Petrillo, S., D\u2019Amico, J., La Rosa, P., Bertini, E.S., and Piemonte, F. (2019). Targeting NRF2 for the treatment of Friedreich\u2019s ataxia: A comparison among drugs. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20205211"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"101791","DOI":"10.1016\/j.redox.2020.101791","article-title":"The Nrf2 induction prevents ferroptosis in Friedreich\u2019s Ataxia","volume":"38","author":"Petrillo","year":"2021","journal-title":"Redox Biol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3389\/fncel.2019.00356","article-title":"Nrf2 induction re-establishes a proper neuronal differentiation program in Friedreich\u2019s ataxia neural stem cells","volume":"13","author":"Russo","year":"2019","journal-title":"Front. Cell. Neurosci."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1093\/hmg\/ddy016","article-title":"Effect of diazoxide on Friedreich ataxia models","volume":"27","author":"Santoro","year":"2018","journal-title":"Hum. Mol. Gene"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1093\/hmg\/ddx141","article-title":"Frataxin deficiency impairs mitochondrial biogenesis in cells, mice and humans","volume":"26","author":"Jasoliya","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Jasoliya, M., Sacca, F., Sahdeo, S., Chedin, F., Pane, C., Brescia Morra, V., Filla, A., Pook, M., and Cortopassi, G. (2019). Dimethyl fumarate dosing in humans increases frataxin expression: A potential therapy for Friedreich\u2019s ataxia. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0217776"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"9840","DOI":"10.1038\/s41598-017-10320-2","article-title":"Peptide SS-31 upregulates frataxin expression and improves the quality of mitochondria: Implications in the treatment of Friedreich ataxia","volume":"7","author":"Zhao","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/hmg\/ddab232","article-title":"SS-31 efficacy in a mouse model of Friedreich ataxia by upregulation of frataxin expression","volume":"31","author":"Liu","year":"2022","journal-title":"Hum. Mol. Genet."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e134221","DOI":"10.1172\/jci.insight.134221","article-title":"Exenatide induces frataxin expression and improves mitochondrial function in Friedreich ataxia","volume":"5","author":"Oliveira","year":"2020","journal-title":"JCI Insight"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"eabe1633","DOI":"10.1126\/scitranslmed.abe1633","article-title":"Treatment with ROS detoxifying gold quantum clusters alleviates the functional decline in a mouse model of Friedreich ataxia","volume":"13","author":"Villa","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1590\/fst.09919","article-title":"Antioxidant-mediated protective role of Hericium erinaceus (Bull.: Fr.) Pers. against oxidative damage in fibroblasts from Friedreich\u2019s ataxia patient","volume":"40","author":"Lew","year":"2020","journal-title":"Food Sci. Technol."},{"key":"ref_128","first-page":"4847","article-title":"Friedreich ataxia-induced pluripotent stem cell-derived neurons show a cellular phenotype that is corrected by a benzamide HDAC inhibitor","volume":"25","author":"Codazzi","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"115993","DOI":"10.1016\/j.bmc.2021.115993","article-title":"Cytoprotective activities of kinetin purine isosteres","volume":"33","author":"Mik","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Calatrava-Ferreras, L., Gonzalo-Gobernado, R., Reimers, D., Herranz, A.S., Casarejos, M.J., Jim\u00e9nez-Escrig, A., Regadera, J., Velasco-Mart\u00edn, J., Vallejo-Mu\u00f1oz, M., and D\u00edaz-Gil, J.J. (2016). Liver growth factor (LGF) upregulates frataxin protein expression and reduces oxidative stress in Friedreich\u2019s ataxia transgenic mice. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17122066"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1016\/j.bmc.2018.05.005","article-title":"Lipophilic methylene blue analogues enhance mitochondrial function and increase frataxin levels in a cellular model of Friedreich\u2019s ataxia","volume":"26","author":"Khdour","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1039\/C8MD00274F","article-title":"Phenothiazine antioxidants increase mitochondrial biogenesis and frataxin levels in Friedreich\u2019s ataxia cells","volume":"9","author":"Khdour","year":"2018","journal-title":"MedChemComm"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.1016\/j.bmc.2017.08.021","article-title":"Lipophilic methylene violet analogues as modulators of mitochondrial function and dysfunction","volume":"25","author":"Khdour","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1021\/acsmedchemlett.0c00293","article-title":"Antiferroptotic activity of phenothiazine analogues: A novel therapeutic strategy for oxidative stress related disease","volume":"11","author":"Liu","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1021\/acschemneuro.0c00323","article-title":"Identification of a novel oleic acid analog with protective effects in multiple cellular models of Friedreich ataxia","volume":"11","author":"Cotticelli","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fncel.2018.00188","article-title":"Novel Nrf2-inducer prevents mitochondrial defects and oxidative stress in Friedreich\u2019s ataxia models","volume":"12","author":"Abeti","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"105162","DOI":"10.1016\/j.nbd.2020.105162","article-title":"PPAR gamma agonist leriglitazone improves frataxin-loss impairments in cellular and animal models of Friedreich ataxia","volume":"148","author":"Britti","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/hmg\/ddy448","article-title":"GRP75 overexpression rescues frataxin deficiency and mitochondrial phenotypes in Friedreich ataxia cellular models","volume":"28","author":"Dong","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Petrillo, S., Piermarini, E., Pastore, A., Vasco, G., Schirinzi, T., Carrozzo, R., Bertini, E., and Piemonte, F. (2017). Nrf2-inducers counteract neurodegeneration in frataxin-silenced motor neurons: Disclosing new therapeutic targets for Friedreich\u2019s ataxia. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18102173"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ymgme.2012.09.007","article-title":"EPI-743 reverses the progression of the pediatric mitochondrial disease\u2013genetically defined Leigh syndrome","volume":"107","author":"Martinelli","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/mds.25058","article-title":"A0001 in Friedreich ataxia: Biochemical characterization and effects in a clinical trial","volume":"27","author":"Lynch","year":"2012","journal-title":"Mov. Disord."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.mam.2008.05.005","article-title":"Regulation of glutathione synthesis","volume":"30","author":"Lu","year":"2009","journal-title":"Mol. Asp. Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2174\/1574890110666151116144725","article-title":"The challenges of blood pressure control in dialysis patients","volume":"10","author":"Campese","year":"2015","journal-title":"Recent Adv. Cardiovasc. Drug Discov."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Virgili, N., Mancera, P., Wappenhans, B., Sorrosal, G., Biber, K., Pugliese, M., and Espinosa-Parrilla, J.F. (2013). KATP channel opener diazoxide prevents neurodegeneration: A new mechanism of action via antioxidative pathway activation. PLoS ONE, 8.","DOI":"10.1371\/annotation\/0e045706-ea24-41db-be90-27d1cbcd35b1"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1515\/crpm-2013-0024","article-title":"Diazoxide treatment for persistent hypoglycemia in a small for gestational age preterm infant with adequate low insulin levels","volume":"3","author":"Arnon","year":"2014","journal-title":"Case Rep. Perinat. Med."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Barroso, M., Moreno-Calder\u00f3n, K.M., S\u00e1nchez-Duarte, E., Cort\u00e9s-Rojo, C., Saavedra-Molina, A., Rodr\u00edguez-Orozco, A.R., and Montoya-P\u00e9rez, R. (2020). Diazoxide and exercise enhance muscle contraction during obesity by decreasing ROS levels, lipid peroxidation, and improving glutathione redox status. Antioxidants, 9.","DOI":"10.3390\/antiox9121232"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"e20190093","DOI":"10.1590\/1678-9199-jvatitd-2019-0093","article-title":"Neuroprotection and immunomodulation by dimethyl fumarate and a heterologous fibrin biopolymer after ventral root avulsion and reimplantation","volume":"26","author":"Kempe","year":"2020","journal-title":"J. Venom. Anim. Toxins Incl. Trop. Dis."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Garcia-Mesa, Y., Xu, H.N., Vance, P., Gruenewald, A.L., Garza, R., Midkiff, C., Alvarez-Hernandez, X., Irwin, D.J., Gill, A.J., and Kolson, D.L. (2021). Dimethyl fumarate, an approved multiple sclerosis treatment, reduces brain oxidative stress in SIV-infected rhesus macaques: Potential therapeutic repurposing for HIV neuroprotection. Antioxidants, 10.","DOI":"10.3390\/antiox10030416"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.tem.2020.02.011","article-title":"Polyphenols as caloric restriction mimetics regulating mitochondrial biogenesis and mitophagy","volume":"31","author":"Davinelli","year":"2020","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1681\/ASN.2010080808","article-title":"Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury","volume":"22","author":"Szeto","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"106546","DOI":"10.1016\/j.yebeh.2019.106546","article-title":"Advances in the treatment of mitochondrial epilepsies","volume":"101","author":"Rahman","year":"2019","journal-title":"Epilepsy Behav."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"7452","DOI":"10.1074\/jbc.RA119.012094","article-title":"The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action: SS-31 modulates lipid bilayer surface electrostatics","volume":"295","author":"Mitchell","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/0250-474X.62228","article-title":"Exenatide: A new promising antidiabetic agent","volume":"72","author":"Chakraborti","year":"2010","journal-title":"Indian J. Pharm. Sci."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Sonia, T.A., and Sharma, C.P. (2014). Diabetes mellitus\u2014An overview. Oral Delivery of Insulin, Elsevier. [1st ed.].","DOI":"10.1533\/9781908818683.1"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1126\/science.aaf4924","article-title":"Permanent excimer superstructures by supramolecular networking of metal quantum clusters","volume":"353","author":"Monguzzi","year":"2016","journal-title":"Science"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"5976","DOI":"10.1038\/s41598-017-05156-9","article-title":"Metal nanoclusters with synergistically engineered optical and buffering activity of intracellular reactive oxygen species by compositional and supramolecular design","volume":"7","author":"Monguzzi","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Chong, P.S., Fung, M.-L., Wong, K.H., and Lim, L.W. (2020). Therapeutic potential of Hericium erinaceus for depressive disorder. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21010163"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"14945","DOI":"10.1038\/s41598-020-71966-z","article-title":"Hericium erinaceus potentially rescues behavioural motor deficits through ERK-CREB-PSD95 neuroprotective mechanisms in rat model of 3-acetylpyridine-induced cerebellar ataxia","volume":"10","author":"Chong","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13020-021-00546-8","article-title":"Neurogenesis-dependent antidepressant-like activity of Hericium erinaceus in an animal model of depression","volume":"16","author":"Chong","year":"2021","journal-title":"Chin. Med."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/s12906-020-03132-x","article-title":"Neuroprotective effects of Hericium erinaceus (Bull.: Fr.) Pers. against high-dose corticosterone-induced oxidative stress in PC-12 cells","volume":"20","author":"Lew","year":"2020","journal-title":"BMC Complement. Med. Ther."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"580752","DOI":"10.1093\/ecam\/neq062","article-title":"Peripheral nerve regeneration following crush injury to rat peroneal nerve by aqueous extract of medicinal mushroom Hericium erinaceus (Bull.: Fr.) Pers. (Aphyllophoromycetideae)","volume":"2011","author":"Wong","year":"2011","journal-title":"Evid. Based Complement. Altern"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1615\/IntJMedMushrooms.v17.i11.40","article-title":"Lion\u2019s mane, Hericium erinaceus and Tiger Milk, Lignosus rhinocerotis (higher basidiomycetes) medicinal mushrooms stimulate neurite outgrowth in dissociated cells of brain, spinal cord, and retina: An in vitro study","volume":"17","author":"Samberkar","year":"2015","journal-title":"Int. J. Med. Mushrooms"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1615\/IntJMedMushrooms.v19.i3.10","article-title":"An overview of culinary and medicinal mushrooms in neurodegeneration and neurotrauma research","volume":"19","author":"Wong","year":"2017","journal-title":"Int. J. Med. Mushrooms"},{"key":"ref_164","first-page":"47","article-title":"Effects of cultivation techniques and processing on antimicrobial and antioxidant activities of Hericium erinaceus (Bull.: Fr.) Pers. extracts","volume":"47","author":"Wong","year":"2009","journal-title":"Food Technol. Biotechnol."},{"key":"ref_165","unstructured":"Egger, G., and Arimodo, P. (2016). Predicting and monitoring responses to epigenetic drugs. Drug Discov. Cancer Epigenetics, Academic Press."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Qiu, X., Rong, X., Yang, J., and Lu, Y. (2019). Evaluation of the antioxidant effects of different histone deacetylase inhibitors (HDACis) on human lens epithelial cells (HLECs) after UVB exposure. BMC Ophthalmol., 19.","DOI":"10.1186\/s12886-019-1056-7"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"R895","DOI":"10.1016\/j.cub.2003.11.006","article-title":"Heterochromatin: Silence is golden","volume":"13","author":"Elgin","year":"2003","journal-title":"Curr. Biol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nchembio815","article-title":"Histone deacetylase inhibitors reverse gene silencing in Friedreich\u2019s ataxia","volume":"2","author":"Herman","year":"2006","journal-title":"Nat. Chem. Biol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"35402","DOI":"10.1074\/jbc.M807045200","article-title":"Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases","volume":"283","author":"Chou","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.chembiol.2009.07.010","article-title":"Chemical probes identify a role for histone deacetylase 3 in Friedreich\u2019s ataxia gene silencing","volume":"16","author":"Xu","year":"2009","journal-title":"Chem. Biol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.cell.2013.07.030","article-title":"A neo-substrate that amplifies catalytic activity of Parkinson\u2019s-disease-related kinase PINK1","volume":"154","author":"Hertz","year":"2013","journal-title":"Cell"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"e7081","DOI":"10.1073\/pnas.1801772115","article-title":"N6-Furfuryladenine is protective in Huntington\u2019s disease models by signaling huntingtin phosphorylation","volume":"115","author":"Bowie","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1369\/jhc.2009.952275","article-title":"Mobilization of neural stem cells and generation of new neurons in 6-OHDA\u2013lesioned rats by intracerebroventricular infusion of liver growth factor","volume":"57","author":"Reimers","year":"2009","journal-title":"J. Histochem. Cytochem."},{"key":"ref_174","first-page":"173","article-title":"Liver growth factor as a tissue regenerating factor in neurodegenerative diseases","volume":"9","author":"Perucho","year":"2014","journal-title":"Recent Pat. CNS Drug Discov."},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Gonzalo-Gobernado, R., Calatrava-Ferreras, L., Reimers, D., Herranz, A.S., Rodr\u00edguez-Serrano, M., Miranda, C., Jim\u00e9nez-Escrig, A., D\u00edaz-Gil, J.J., and Baz\u00e1n, E. (2013). Neuroprotective activity of peripherally administered liver growth factor in a rat model of Parkinson\u2019s disease. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0067771"},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Gonzalo-Gobernado, R., Perucho, J., Vallejo-Mu\u00f1oz, M., Casarejos, M.J., Reimers, D., Jim\u00e9nez-Escrig, A., G\u00f3mez, A., Ulzurrun de Asanza, G.M., and Baz\u00e1n, E. (2020). Liver growth factor \u201cLGF\u201d as a therapeutic agent for Alzheimer\u2019s disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21239201"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1369\/jhc.5A6805.2005","article-title":"Intrastriatal infusion of liver growth factor stimulates dopamine terminal sprouting and partially restores motor function in 6-hydroxydopamine-lesioned rats","volume":"54","author":"Reimers","year":"2006","journal-title":"J. Histochem. Cytochem."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1073274817729070","DOI":"10.1177\/1073274817729070","article-title":"Serotonin syndrome complicating treatment of ifosfamide neurotoxicity with methylene blue","volume":"24","author":"Snyder","year":"2017","journal-title":"Cancer Control"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1124\/jpet.114.219352","article-title":"Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer\u2019s disease","volume":"352","author":"Baddeley","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1007\/s12035-017-0712-2","article-title":"From mitochondrial function to neuroprotection-an emerging role for methylene blue","volume":"55","author":"Tucker","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"ref_181","first-page":"11","article-title":"Review on various uses of N-acetyl cysteine","volume":"19","author":"Mokhtari","year":"2017","journal-title":"Cell J."},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Shramko, V.S., Polonskaya, Y.V., Kashtanova, E.V., Stakhneva, E.M., and Ragino, Y.I. (2020). The short overview on the relevance of fatty acids for human cardiovascular disorders. Biomolecules, 10.","DOI":"10.3390\/biom10081127"},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Probst, B.L., Trevino, I., McCauley, L., Bumeister, R., Dulubova, I., Wigley, W.C., and Ferguson, D.A. (2015). RTA 408, A novel synthetic triterpenoid with broad anticancer and anti-inflammatory activity. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0122942"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/brain\/awy071","article-title":"KEAP1 inhibition is neuroprotective and suppresses the development of epilepsy","volume":"141","author":"Eckel","year":"2018","journal-title":"Brain"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"101309","DOI":"10.1016\/j.redox.2019.101309","article-title":"The Nrf2 activator RTA-408 attenuates osteoclastogenesis by inhibiting STING dependent NF-\u03bab signaling","volume":"28","author":"Sun","year":"2020","journal-title":"Redox Biol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"e1515","DOI":"10.1038\/cddis.2014.458","article-title":"PGC-1 \u03b1 buffers ROS-mediated removal of mitochondria during myogenesis","volume":"5","author":"Baldelli","year":"2014","journal-title":"Cell Death Dis."},{"key":"ref_187","first-page":"1452696","article-title":"PGC-1\u03b1, inflammation, and oxidative stress: An integrative view in metabolism","volume":"2020","author":"Ortega","year":"2020","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/nure.12060","article-title":"Sulforaphane: Translational research from laboratory bench to clinic","volume":"71","author":"Houghton","year":"2013","journal-title":"Nutr. Rev."},{"key":"ref_189","unstructured":"Bathaie, Z., and Tamanoi, F. (2015). Mechanisms of the anticancer effects of isothiocyanates. Enzyme, Academic Press."},{"key":"ref_190","doi-asserted-by":"crossref","unstructured":"Tollefsbol, T.O. (2015). Nutriepigenomics: Personalized nutrition meets epigenetics. Personalized Epigenetics, Elsevier. [1st ed.].","DOI":"10.1016\/B978-0-12-420135-4.00001-2"},{"key":"ref_191","unstructured":"Bishayee, A., and Bhatia, D. (2019). Epigenetic dietary interventions for prevention of cancer. Epigenetics of Cancer Prevention, Academic Press."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","article-title":"Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease","volume":"171","author":"Stockwell","year":"2017","journal-title":"Cell"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"NS20180060","DOI":"10.1042\/NS20180060","article-title":"Role of frataxin protein deficiency and metabolic dysfunction in Friedreich ataxia, an autosomal recessive mitochondrial disease","volume":"2","author":"Clark","year":"2018","journal-title":"Neuronal Signal."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/acn3.660","article-title":"Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia","volume":"6","author":"Lynch","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1038\/s41467-020-18305-y","article-title":"Predicting the frequencies of drug side effects","volume":"11","author":"Galeano","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_196","first-page":"711","article-title":"Combination effects of curcumin and aqueous extract of Lignosus rhinocerotis mycelium on neurite outgrowth stimulation activity in PC-12 cells","volume":"8","author":"John","year":"2013","journal-title":"Nat. Prod. Commun."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1002\/cpph.67","article-title":"Natural products as a foundation for drug discovery","volume":"86","author":"Beutler","year":"2019","journal-title":"Curr. Protoc. Pharmacol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.biotechadv.2015.08.001","article-title":"Discovery and resupply of pharmacologically active plant-derived natural products: A review","volume":"33","author":"Atanasov","year":"2015","journal-title":"Biotechnol. Adv."},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Faouzi, A., and Roullin, V.G. (2021). Think big, start small: How nanomedicine could alleviate the burden of rare CNS diseases. Pharmaceuticals, 14.","DOI":"10.3390\/ph14020109"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"19282","DOI":"10.1038\/s41598-019-55799-z","article-title":"A new tool to determine the cellular metabolic landscape: Nanotechnology to the study of Friedreich\u2019s ataxia","volume":"9","author":"Vannocci","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"Uceda, A.B., Donoso, J., Frau, J., Vilanova, B., and Adrover, M. (2021). Frataxins emerge as new players of the intracellular antioxidant machinery. Antioxidants, 10.","DOI":"10.3390\/antiox10020315"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"104994","DOI":"10.1016\/j.phrs.2020.104994","article-title":"Treatment of dilated cardiomyopathy in a mouse model of Friedreich\u2019s ataxia using N-acetylcysteine and identification of alterations in microRNA expression that could be involved in its pathogenesis","volume":"159","author":"Chiang","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/archneur.64.4.558","article-title":"Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up","volume":"64","author":"Ribai","year":"2007","journal-title":"Arch. Neurol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"19911","DOI":"10.1074\/jbc.M412443200","article-title":"Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species","volume":"280","author":"Singh","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.3346\/jkms.2011.26.11.1474","article-title":"Sulforaphane induces antioxidative and antiproliferative responses by generating reactive oxygen species in human bronchial epithelial BEAS-2B cells","volume":"26","author":"Lee","year":"2011","journal-title":"J. Korean Med. Sci."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1017\/S0317167100003498","article-title":"Malaysian siblings with Friedreich ataxia and chorea: A novel deletion in the frataxin gene","volume":"31","author":"Spacey","year":"2004","journal-title":"Can. J. Neurol. Sci."},{"key":"ref_207","doi-asserted-by":"crossref","unstructured":"Salehi, M.H., Kamalidehghan, B., Houshmand, M., Yong Meng, G., Sadeghizadeh, M., Aryani, O., and Nafissi, S. (2014). Gene expression profiling of mitochondrial oxidative phosphorylation (OXPHOS) complex I in Friedreich ataxia (FRDA) patients. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0094069"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2053-8871-1-4","article-title":"From mice to men: Lessons from mutant ataxic mice","volume":"1","author":"Cendelin","year":"2014","journal-title":"Cerebellum Ataxias"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-019-0089-y","article-title":"Applications of genome editing technology in the targeted therapy of human diseases: Mechanisms, advances and prospects","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijsu.2019.10.015","article-title":"The current state of animal models in research: A review","volume":"72","author":"Robinson","year":"2019","journal-title":"Int. J. Surg."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/6\/764\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:35:00Z","timestamp":1760139300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/6\/764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,19]]},"references-count":210,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["ph15060764"],"URL":"https:\/\/doi.org\/10.3390\/ph15060764","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,19]]}}}